2nd firm agrees to temporary shutdown in outbreak

by Jay Lindsay
This photo provided Oct. 9, 2012, by the Minnesota Department of Health shows shows vials of the injectable steroid product made by New England Compounding Center implicated in a fungal meningitis outbreak that were being shipped to the Centers for Disease Control and Prevention in Atlanta from Minneapolis. About 17,700 single-dose vials of the steroid sent to 23 states have been recalled. The outbreak involves 10 states, including Minnesota. (AP Photo/Minnesota Department of Health)

(AP)—A Massachusetts company run by the same executives who operated a specialty pharmacy linked to a fatal meningitis outbreak has agreed to temporarily shut down for inspection by state and federal regulators.

Ameridose is located in Westborough, Mass. The Compounding Center, which produced a steroid linked to the outbreak, is in Framingham. Both firms are run by Barry Cadden and Greg Conigliaro.

Ameridose provides sterile medication in prefilled oral syringes to about 3,000 hospitals nationwide. It opened its doors in 2006, eight years after NECC opened.

The Massachusetts Department of Public Health says Ameridose agreed to the shutdown until inspections by and the U.S. are completed.

There is no recall of Ameridose products.

The outbreak has sickened 137 people in 10 states. Twelve have died.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Mass. gov: Drug firm may have misled regulators

Oct 10, 2012

(AP)—Massachusetts Gov. Deval Patrick says the specialty pharmacy linked to a deadly meningitis outbreak may have misled regulators and done work beyond the scope of its state license.

US pharmacy linked to outbreak issues wide recall

Oct 07, 2012

(AP)—The pharmacy that distributed a steroid linked to an outbreak of fungal meningitis has issued a voluntary recall of all of its products, calling the move a precautionary measure.

Recommended for you

Ebola vaccine not before late 2016: GSK researcher

Oct 17, 2014

An Ebola vaccine by British pharmaceuticals giant GlaxoSmithKline may not be ready for commercial use until late 2016 and should therefore not be seen as the "primary answer" to the current outbreak, a company researcher ...

Chimerix gets FDA OK to test drug for Ebola

Oct 17, 2014

(AP)—A North Carolina drugmaker plans to test its experimental antiviral drug in patients who have Ebola, after getting authorization from regulators at the Food and Drug Administration.

Esbriet, ofev approved to treat deadly lung disease

Oct 16, 2014

(HealthDay)—Two new drugs have been approved by the U.S. Food and Drug Administration to treat progressive lung scarring from an uncertain cause, medically called idiopathic pulmonary fibrosis (IPF).

FDA weighs removing bolded warning from Chantix

Oct 14, 2014

(AP)—The Food and Drug Administration will ask a panel of experts later this week whether a bold-letter warning on the anti-smoking drug Chantix should be removed based on company-supported evidence that the drug does not ...

Drug-coated balloon catheter approved

Oct 13, 2014

(HealthDay)—The first drug-coated balloon catheter designed to clear narrowed or blocked arteries in the thigh and knee has been approved by the U.S. Food and Drug Administration.

User comments